Tricyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos Patents (Class 514/220)
-
Publication number: 20080255097Abstract: The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. More specifically, the present invention relates to methods of and compositions for treating and relieving symptoms associated with substance abuse and withdrawal. The present invention relates to methods of and compositions for treating and relieving symptoms associated with addiction to antidepressants, opiates, nicotine or marijuana. In one method, a patient is treated with a composition that directly or indirectly modulates GABAA by modulating the expression of the GABAA receptor a4 subunit.Type: ApplicationFiled: April 7, 2006Publication date: October 16, 2008Applicant: Hythiam, Inc.Inventors: Sanjay Sabnani, Donald Wesson, Joseph Dunn
-
Publication number: 20080255030Abstract: The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein.Type: ApplicationFiled: August 6, 2007Publication date: October 16, 2008Inventors: Xing-Xian Yu, Sanjay Bhanot
-
Publication number: 20080255096Abstract: The present invention relates to a substance for the treatment of the phantom phenomena of acute tinnitus and/or phantom pain, a method for the diagnosis and for the treatment of these phantom phenomena.Type: ApplicationFiled: January 19, 2006Publication date: October 16, 2008Inventors: Marlies Knipper-Breer, Lukas Ruttiger
-
Patent number: 7435730Abstract: The present invention provides a compound of formula (I): wherein all variables are as defined herein, pharmaceutical formulations containing the same, processes for preparing the same and their use therapy.Type: GrantFiled: January 5, 2007Date of Patent: October 14, 2008Assignee: CeNeS LimitedInventors: Paul L. Feldman, David Kendall Jung, Istvan Kaldor, Gregory J. Pacofsky, Jeffrey A. Stafford, Jeffrey H. Tidwell
-
Publication number: 20080248123Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: ApplicationFiled: March 26, 2008Publication date: October 9, 2008Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
-
Publication number: 20080249082Abstract: The present invention relates to the treatment of compulsive, impulsive and pervasive developmental disorders. More particularly, the methods described herein comprise administration of memantine to an individual suffering from such a disorder in an amount effective to relieve one or more symptoms of said disorder.Type: ApplicationFiled: September 19, 2005Publication date: October 9, 2008Applicant: Mount Sinai School of MedicineInventor: Eric Hollander
-
Publication number: 20080241289Abstract: Disclosed herein are non-nucleoside reverse transcriptase inhibitors having structural Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and the methods of their use thereof.Type: ApplicationFiled: February 22, 2008Publication date: October 2, 2008Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7429578Abstract: Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.Type: GrantFiled: September 6, 2005Date of Patent: September 30, 2008Assignees: Agouron Pharmaceuticals, Inc., Cancer Research Campaign Technology LimitedInventors: Stephen Evan Webber, Stacie S. Canan-Koch, Jayashree Tikhe, Lars Henrik Thoresen
-
Patent number: 7429580Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.Type: GrantFiled: January 11, 2005Date of Patent: September 30, 2008Assignees: Orexigen Therapeutics, Inc., Duke UniversityInventors: Kishore M. Gadde, K. Ranga R. Krishnan
-
Publication number: 20080234250Abstract: The invention concerns compounds according to general formulae 1, wherein G1 is an amine. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.Type: ApplicationFiled: August 18, 2005Publication date: September 25, 2008Inventor: Gary Robert William Pitt
-
Publication number: 20080234254Abstract: The present invention relates to a benzamide derivative comprising a head, spacer and cap group wherein the spacer includes a benzene ring substituted with an additional spacer and wherein the additional spacer is an unsaturated group.Type: ApplicationFiled: June 7, 2005Publication date: September 25, 2008Applicant: UNIVERSITY OF LEEDSInventors: Ronald Grigg, Andrew Cook
-
Publication number: 20080221084Abstract: The present invention relates to a method for reducing infarction comprising administering to a patient ion need thereof a therapeutically effective amount of a composition comprising as an active ingredient a vasopressin antagonist compound and to a composition useful therefor. The present invention also relates to a method for reducing infarction comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a vasopressin antagonist compound and a beta-blocker and to combinations useful therefor. The methods, compositions and combinations of the present invention can be used for reducing infarction in the heart (myocardial infarction) and the brain (stroke).Type: ApplicationFiled: October 29, 2007Publication date: September 11, 2008Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Yongge LIU, Junichi KAMBAYASHI, Hiroyuki FUJIKI, Toyoki MORI
-
Publication number: 20080214525Abstract: A compound of formula (I); or a salt or solvate thereof, wherein: the dotted line indicates the optional presence of a double bond between C2 and C3; R2 is selected from —H, —OH, =0, ?CH2, —CN, —R, OR, halo, ?CH—R, O—SO2—R, CO2R and COR; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo, where R and R? are independently selected from optionally substituted C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R10 and R11 either together form a double bond, or are selected from H and YRY, where Y is selected from O, S and NH and R is H or C1-7 alkyl or H and SOxM, where x is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; each X is independently a heteroarylene group; n is from 1 to 6; and RE is C1-4 alkyl. The compound is useful for the treatment of proliferative diseases.Type: ApplicationFiled: October 5, 2006Publication date: September 4, 2008Applicant: SPIROGEN LIMITEDInventors: Philip Wilson Howard, David Edwin Thurston, Geoffrey Wells
-
Publication number: 20080207599Abstract: The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABAA chloride channel activity to treat alcohol and/or stimulant substance abuse. The present invention also relates to methods of, and protocols for, relieving symptoms associated with alcohol and/or stimulant substance abuse in a comprehensive treatment plan. More specifically, the present invention relates to the use of a selective chloride channel modulator, such as flumazenil, to treat alcohol and/or psychostimulant dependency, the withdrawal symptoms associated therewith, and the cravings associated therewith.Type: ApplicationFiled: May 13, 2008Publication date: August 28, 2008Applicant: Hythiam, Inc.Inventor: Juan Jose Legarda Ibanez
-
Publication number: 20080188465Abstract: A process for the preparation of polymorph Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2.3-b][1,5]benzodiazepine, or olanzapine.Type: ApplicationFiled: October 30, 2007Publication date: August 7, 2008Inventors: Hiren V. Patel, Anup K. Ray, Pramod B. Patel, Mahendra R. Patel
-
Patent number: 7407949Abstract: Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or V1a receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.Type: GrantFiled: February 12, 2004Date of Patent: August 5, 2008Assignee: Ferring B.V.Inventors: Peter Hudson, Andrzej Roman Batt, Celine Marguerite Simone Heeney, Andrew John Baxter, Michael Bryan Roe, Peter Andrew Robson
-
Patent number: 7407951Abstract: Compounds of formula (I): formula (I) and salts, solvates, chemically protected forms, and prodrugs thereof, are disclosed wherein R2 is selected from: an optionally substituted napthyl group; an optionally substituted thiophenyl or furanyl group; and a phenyl group substituted by: one or more chloro or fluoro groups; an ethyl or propyl group; a 4-t-butyl group; a 2-methyl group; or two methyl groups in the 2- and 6-positions.Type: GrantFiled: November 14, 2003Date of Patent: August 5, 2008Assignee: Spirogen LimitedInventors: David Edwin Thurston, Philip Wilson Howard
-
Publication number: 20080176835Abstract: A family of imidazole compounds useful for inhibiting the activity of prenyl transferases. The compounds are covered by the following formula: wherein X is (CHR11)n3(CH2)n4Z(CH2)n5 where Z is O, N(R12), S, or a bond; Y is CO, CH2, CS, or a bond; R1 is or N(R24R25); and the remaining substituents are as defined in the disclosure.Type: ApplicationFiled: October 30, 2007Publication date: July 24, 2008Inventors: Thomas D. Gordon, Barry A. Morgan
-
Publication number: 20080166406Abstract: A rapidly disintegrating dosage form containing magnesium carbonate heavy is described, which disintegrates upon contact with moisture. The dosage forms can be either dispersible or orodispersible tablets and can accommodate widely different active principles. The magnesium carbonate heavy is found to be an excellent dispersant under basic and neutral conditions, and gives the tablets a smooth mouth-feel.Type: ApplicationFiled: March 2, 2006Publication date: July 10, 2008Inventor: Torfi E. Kristjansson
-
Publication number: 20080167293Abstract: Compounds of the formula: (I) or solvate thereof, wherein: R2 is an optionally substituted C5-20 aryl group; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NHRR?, nitro, Me3Sn and halo; R? is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings; X is selected from O, S, or NH; z is 2 or 3; M is a monovalent pharmaceutically acceptable cation; R2?, R6?, R7?, R9?, X? and M? are selected from the same groups as R2, R6, R7, R9, X and M respectively, or M and M? may together represent a divalent pharmaceutically acceptable cation.Type: ApplicationFiled: April 21, 2006Publication date: July 10, 2008Applicant: Spirogen LimitedInventors: Philip Wilson Howard, Zhizhi Chen, Stephen John Gregson
-
Publication number: 20080167289Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.Type: ApplicationFiled: February 13, 2007Publication date: July 10, 2008Inventors: David Kay, Ronald Knegtel, Jean-Damien Charrier, Heather Twin
-
Publication number: 20080161292Abstract: Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed.Type: ApplicationFiled: December 27, 2007Publication date: July 3, 2008Applicant: Abbott LaboratoriesInventors: Vincent L. Giranda, Julie M. Miyashiro, Thomas D. Penning, Keith W. Woods
-
Publication number: 20080161291Abstract: The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, to pharmaceutical compositions comprising them and to methods of treating neoplastic conditions.Type: ApplicationFiled: December 21, 2007Publication date: July 3, 2008Inventors: James B. McAlpine, Arjun H. Banskota, Mustapha Aouidate
-
Publication number: 20080146548Abstract: This disclosure relates to amides, aryl sulphonamides, aryl ureas, and ?,?-diketones derivatives useful as carboxylesterase esterase inhibitors. The disclosure is also directed to the use of these compounds as selective human intestinal carboxylesterase inhibitors and insect carboxylesterase inhibitors. The disclosure is also directed to pharmaceutical compositions and pesticide formulations containing these compounds, and to methods for treating or ameliorating the toxic effects following administration of drugs such as cancer therapy drugs, treating or ameliorating the effects of a drug overdose, and to the use of the compounds for increasing the effectiveness of insecticides and pesticides.Type: ApplicationFiled: February 15, 2008Publication date: June 19, 2008Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Philip M. Potter, Janice L. Hyatt, Christopher L. Morton, Paul P. Beroza, Komath V. Damoradan
-
Publication number: 20080146541Abstract: A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT2A) and a dopamine type 2 (D2) receptors.Type: ApplicationFiled: December 13, 2006Publication date: June 19, 2008Inventor: Hung-Ming Wu
-
Publication number: 20080138409Abstract: An olanzapine pharmaceutical composition such as a tablet is made using anhydrous lactose as an excipient.Type: ApplicationFiled: September 28, 2007Publication date: June 12, 2008Inventor: Niels J. Osinga
-
Patent number: 7384935Abstract: This invention relates to phosphate prodrugs of a farnesylated dibenzodiazepinone, to processes of their manufacture, to pharmaceutical compositions comprising the prodrugs, and to their use in the treatment of neoplasms.Type: GrantFiled: September 27, 2006Date of Patent: June 10, 2008Assignee: Thallion Pharmaceuticals, Inc.Inventors: Mustapha Aouidate, James B. McAlpine, Faustinus Yeboah, Ashraf Ibrahim, Arjun H. Banskota, Maxime Ranger, Gregory L. White
-
Patent number: 7384934Abstract: Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C1-4) alkylene or hydroxy substituted (C1-4) alkylene; X is oxygen or sulfur; R1 is hydrogen, (C1-6) fluroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, or —CN; R2 is H, halogen, (C1-6) fluoroalkyl, (C1-6) cycloalkyl, OR4, SR4, NO2, CN, COR4, C(O)OR4, CONR5R6, NR5R6, SO2NR5R6, NR5COR4, NR5SO2R4, optionally substituted aromatic, or (C1-6) alkyl, wherein (C1-6) alkyl is unsubstituted or substituted with a hydroxy group; R3 is hydrogen (C1-6) fluoroalkyl, (C2-6) alkenyl, Ar, (C1-4)alkyl-Ar, or (C1-4) alkyl wherein (C1-4) alkyly is unsubstituted or substituted with a phenyl; R4 is hydrogen, (C1-6) alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionallyType: GrantFiled: July 28, 2003Date of Patent: June 10, 2008Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Zhaogen Chen, Yvan LeHuerou, Fionna Mitchell Martin, Marta Maria Pineiro-Nunez, Vincent Patrick Rocco, Kevin Michael Ruley, John Mehnert Schaus, Patrick Gianpietro Spinazze, David Edward Tupper
-
Publication number: 20080132482Abstract: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.Type: ApplicationFiled: February 1, 2008Publication date: June 5, 2008Applicant: Bristol-Myers Squibb Pharma CompanyInventors: Richard E. Olson, Hong Liu, Lorin A. Thompson
-
Publication number: 20080132492Abstract: The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.Type: ApplicationFiled: February 6, 2008Publication date: June 5, 2008Applicant: Hythiam, Inc.Inventor: Juan Jose Legarda Ibanez
-
Publication number: 20080124407Abstract: The present invention is directed to a method of inhibiting CYP3A4 induction. The method involves administering a compound of the following formula: R1—X—(CH2)n—N?C?S with R1, X, and n defined herein, binds to a Pregnane X Receptor or Steroid and Xenobiotic Receptor (SXR or NR1I2) under conditions effective to inhibit CYP3A4 gene induction. The present invention also include a method of administering a compound, described herein, together with the CYP3A4 inducer to prevent a loss of efficacy in the subject to whom the CYP3A4 inducer is repeatedly administered. In addition, such compounds can be administered to block the interaction between a CYP3A4 inducer and another drug being administered that is a substrate of CYP3A4.Type: ApplicationFiled: October 4, 2007Publication date: May 29, 2008Applicant: UNIVERSITY OF WASHINGTONInventors: David L. Eaton, Kenneth Thummel, Changcheng Zhou, Theo Bammler
-
Publication number: 20080112978Abstract: A method for treatment of HIV infection includes administering at least one anti-HIV drug, such as a reverse transcriptase inhibitor, to a patient in need of such treatment and administering an extract from inflammatory tissue inoculated with vaccinia virus to the patient following the administration of the at least one anti-HIV drug. The extract maintains suppressive action on HIV replication, even if the administration of the anti-HIV drug is terminated.Type: ApplicationFiled: December 15, 2005Publication date: May 15, 2008Inventors: Aftab A. Ansari, M. Eric Gershwin
-
Publication number: 20080113969Abstract: The present invention provides synergistic combinations for the treatment of conditions associated with pain including acute pain, e.g., postoperative pain, chronic pain, inflammatory pain, neuropathic pain and pain associated with migraine. In particular, the present invention relates to the use of an allosteric adenosine A1 receptor enhancer in conjunction with opioid analgesics or 2-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate antagonists for alleviating pain, e.g., postoperative pain.Type: ApplicationFiled: October 16, 2007Publication date: May 15, 2008Inventor: James Conrad Eisenach
-
Publication number: 20080108602Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.Type: ApplicationFiled: March 19, 2007Publication date: May 8, 2008Inventors: Peter Literati Nagy, Jesse Roth, Zoltan Szilvassy, Kalman Tory, Mike Brownstein, Kalman Takacs, Laszlo Vigh, Jozsef Mandi, Balazs Sumegi, Sandor Bernath, Attila Kolonics, Gabor Balogh, Janos Egri
-
Publication number: 20080096870Abstract: The subject invention pertains to methods of treating mental illnesses or conditions characterized by a decreased function of NMDA receptors and/or excessively enhanced glutamate release and activity of non-NMDA receptors (AMPA and/or kainate). Specifically disclosed are methods utilizing BrPhe, or isomers of analogs thereof, for treating or preventing mental illness or conditions such as schizophrenia.Type: ApplicationFiled: July 18, 2005Publication date: April 24, 2008Inventors: Anatoly E. Martynyuk, Donn M. Dennis, Nikolaus Gravenstein, Alexander V. Glushakov, Viktor Yarotskyy, Colin Sumners, Christoph Seubert
-
Publication number: 20080090812Abstract: A pyrrolobenzodiazepine dimer compound of Formula (I): or pharmaceutically acceptable salt or solvate thereof is useful as a therapeutic agent for the treatment of leukaemias, especially B-cell leukaemias, that exhibit resistance to other chemotherapeutic drugs, wherein: the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; R2 and R3 are independently selected from —H, ?O, ?CH2, —CN, —R, OR, halo, ?CH—R, O—SO2—R, CO2R and COR; R6, R7 and R9 are independently selected from II, R, OII, OR, SII, SR, NII2, NIIR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R10 is a carbamate-based nitrogen protecting group and R15 is either O—R11, wherein R is an oxygen protecting group, or OH, or R10 and R15 together form a double bond between N10 and C11; R? is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings, and each X isType: ApplicationFiled: May 5, 2005Publication date: April 17, 2008Applicant: SPIROGEN LIMITEDInventors: Christopher John Pepper, David Edwid Thurston
-
Patent number: 7358241Abstract: This invention relates to methods of inhibiting growth and/or proliferation of a neoplastic cell, and methods of treating neoplasms using the farnesylated dibenzodiazepinone compound of Formula I.Type: GrantFiled: May 16, 2005Date of Patent: April 15, 2008Assignee: Thallion Pharmaceuticals, Inc.Inventors: Pierre Falardeau, Francois Berger, Henriette Gourdeau, James B. McAlpine, Chris M. Farnet, Violetta Dimitriadou
-
Patent number: 7358242Abstract: This invention relates to CCK-A agonists of Formula (I) wherein R1-R4, A, B, X, D, E and G are as defined in the specification, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating diabetes.Type: GrantFiled: July 20, 2007Date of Patent: April 15, 2008Assignee: Pfizer Inc.Inventors: Richard L. Elliott, Kimberly O. Cameron, Marlys Hammond
-
Patent number: 7355047Abstract: Substituted quinolone carboxylic acids and their derivatives are described. These compounds modulate the effect of ?-aminobutyric acid (GABA) via a novel site on the GABAA receptor complex in a therapeutically relevant fashion and may be used to ameliorate CNS disorders amenable to modulation of the GABAA receptor complex.Type: GrantFiled: May 12, 2003Date of Patent: April 8, 2008Assignee: The Regents of the University of CaliforniaInventors: Timothy B. C. Johnstone, Derk J. Hogenkamp, Kelvin W. Gee
-
Publication number: 20080081806Abstract: A new treatment methodology and pharmacological composition for the treatment and remission of Parkinson's Disease and other neurological diseases are provided. The medication and treatment are based on the use of a combination of a phosphodiesterase inhibitor medication, commonly used to treat male erectile dysfunction, and a high-dose of serotonergic synaptic reuptake inhibitor medication, commonly used to treat depression, anxiety disorders, obsessive compulsive disorder and various panic phobias. The treatment regime is based upon the discovery that the primary cause of PD and various other related neurological conditions is dysfunction in the serotonergic pathways involving the brainstem, nucleus of Raphe, and various projecting serotonergic fibers.Type: ApplicationFiled: October 2, 2006Publication date: April 3, 2008Inventor: Jerry M. Held
-
Patent number: 7351701Abstract: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.Type: GrantFiled: July 23, 2004Date of Patent: April 1, 2008Assignees: Cancer Research Technology Limited, Pfizer, Inc.Inventors: Thomas Helleday, Nicola Curtin
-
Patent number: 7348321Abstract: The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.Type: GrantFiled: July 15, 2003Date of Patent: March 25, 2008Assignee: Hythiam, Inc.Inventor: Juan Jose Legarda Ibañez
-
Publication number: 20080045511Abstract: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 and X5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.Type: ApplicationFiled: August 15, 2007Publication date: February 21, 2008Inventors: Joshua Kennedy-Smith, Wylie Solang Palmer, Zachary Kevin Sweeney
-
Patent number: 7329653Abstract: The present invention provides compounds of the general formulas: wherein Y is NR or —(CH2)n; R is H or alkyl; “Z” represents optionally substituted phenyl or a 6-membered aromatic ring having one nitrogen atom; “W” represents a optionally substituted phenyl or 5-membered aromatic ring having one nitrogen atom; “X” represents an optionally substituted 5-membered aromatic ring having one sulfur atom; as well as methods and pharmaceutical compositions utilizing these compounds for the inducing temporary delay of urination or treatment of disorders remedied by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, or bleeding and coagulation disorders.Type: GrantFiled: April 11, 2006Date of Patent: February 12, 2008Assignee: WyethInventors: Amedeo A. Failli, Jay S. Shumsky, Thomas J. Caggiano, John P. Dusza, Kevin A. Memoli
-
Patent number: 7326701Abstract: An agent for increasing the sugar-transporting capacity and an agent for preventing and/or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which contains a lactam compound or a pharmaceutically acceptable salt thereof as the active ingredient.Type: GrantFiled: April 6, 2006Date of Patent: February 5, 2008Assignee: Ajinomoto Co., Inc.Inventors: Yukio Iino, Takao Ikenoue, Nobuo Kondo, Hiroyuki Matsueda, Toshihiro Hatanaka, Ryusuke Hirama, Yoko Masuzawa, Fumio Ohta, Akiyo Yamazaki, Seiji Niwa, Takashi Yamamoto
-
Patent number: 7326700Abstract: The present invention provides tricyclic carboxamide compounds and methods and pharmaceutical compositions for their use in treatment, prevention, or suppression of disorders which may be remedied or alleviated by oxytocin antagonist activity, including prevention and/or suppression of preterm labor, suppression of labor at term prior to caesarean deliver, and for the treatment of dysmenorrhea. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.Type: GrantFiled: April 10, 2002Date of Patent: February 5, 2008Assignee: WyethInventors: Amedeo Arturo Failli, Eugene John Trybulski, Jay Scott Shumsky, William Jennings Sanders
-
Publication number: 20080026081Abstract: The present invention relates to methods of treatment using the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, as a sole active agent or in combination with other pharmacological agents.Type: ApplicationFiled: November 19, 2004Publication date: January 31, 2008Inventors: Axel Unterbeck, Michael De Vivo, Gregory M. Rose
-
Patent number: 7323459Abstract: The invention is directed to a series of novel crystalline olanzapine forms, in particular hydrated and solvated crystalline forms of olanzapine, methods of use in pharmaceutical compositions, and method of treating psychiatric disorders using the crystalline forms. One series of the crystalline forms are hydrates, i.e. water containing crystals, wherein water may be present in a ratio of about 2:1.5 to a ratio of about 1:3 olanzapine:water, while another includes solvates such as an isobutanol solvate. The olanzapine crystalline forms include Forms H, G, Y, X, K, S, Q, Z, and J.Type: GrantFiled: December 24, 2003Date of Patent: January 29, 2008Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Ben Zion Dolitzky, Judith Aronhime, Dov Diller
-
Patent number: 7323458Abstract: The invention concerns a benzodiazepin derivative of formula (I) and their use for treating dyslipidemia, atherosclerosis, diabetes and its complications.Type: GrantFiled: July 4, 2000Date of Patent: January 29, 2008Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Jean-Jacques Berthelon, Daniel Guerrier, Michel Brunet, Jean-Jacques Zeiller, Francis Contard, Fréderic Ausseil
-
Patent number: RE40033Abstract: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system.Type: GrantFiled: December 18, 2001Date of Patent: January 22, 2008Assignee: Eli Lilly and CompanyInventors: Reba Chakrabarti, Terrence Michael Hotten, David Edward Tupper, Jiban Kumar Chakrabarti